A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma after previous therapy with checkpoint inhibitor treatment

Type of Cancer
Renal Cancer

Site
Hackensack

Sponsor
Novartis

Protocol Number
CPZP034A2410

Phase of Trial
Phase II

To Learn More Call
(201)-510-0950